Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drisapersen Phase I/II Extension in Duchenne Muscular Dystrophy
NCT01910649Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Mar 2008
- Primary completion
- Sep 2016
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
01
Overview
A Phase 2 trial of drisapersen in Duchenne muscular dystrophy (DMD), sponsored by BioMarin Pharmaceutical. Started Mar 2008; status: terminated.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01910649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01910649.